Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff Effects

Wed Jan 16, 2013 8:02am EST

* Reuters is not responsible for the content in this press release.

Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff
Effects

LONDON, January 16, 2013 /PRNewswire/ --

    All companies mentioned in the release below have received technical review as of
the close of yesterday's session. These reports are available for free at
http://www.stockcall.com/register  

    For many major drug manufacturers, including Pfizer Inc. 
[http://www.stockcall.com/PFE011613.pdf ](1) (NYSE : PFE) and Merck & Co. Inc.
[http://www.stockcall.com/MRK011613.pdf ](2) (NYSE : MRK), the so-called "patent cliff"
put a major dent in sales and profits. The loss of exclusivity of many blockbuster drugs
allowed generics to be made, and major drug companies have been left to compete with
generic versions that are, in most cases, cheaper.  

    One of the historically best-selling drug which went off-patent in November 2011 is
Lipitor. The anti-cholesterol drug was Pfizer's golden goose as it earned the company
close to $9.6 billion in revenue in 2011. Merck & Co. also suffered from patent loss
with some of its blockbuster drugs such as Singulair, Maxalt, Cozaar/Hyzaar fell off the
patent cliff. But these companies have learnt to survive. Register with us today and
access the technical report in Merck & Co. at  

    http://www.StockCall.com/MRK011613.pdf  

    While several brand-name drug companies have come out with their own generic
equivalents, sales have still suffered. Successful marketing abroad has also helped to
boost sales for select companies; however; numbers are still down from exclusivity
highs. Depressed sales for some could be set to rebound though, as companies are
succeeding in bringing a slew of exciting, new products to market.  

    A number of major drug manufacturers are currently focusing their attention on and
receiving FDA or European Commission approval, which if granted creates the potential
for big returns. Pfizer recently announced that the European Commission gave its
approval to expand the company's pneumococcal conjugate vaccine, Prevenar 13 to children
and adolescents between the ages of 6 to 17 years. The vaccine is for active
immunization for the prevention of invasive disease, pneumonia and acute otitis media
caused by vaccine-type Streptococcus pneumoniae.  

    Additionally, industry players are developing treatments and diagnostic methods for
a number of conditions, including cancer, Pneumonia, cardiovascular diseases and
Alzheimer's among others. With a number of these products newly on the market, it will
be interesting to see which, if any, become the next big bread winners for major drug
manufacturers.  

    Footer:  

        
        1) Pfizer Inc. Technical Analysis [
          http://www.StockCall.com/PFE011613.pdf ]
        2) Merck & Co. Inc. Technical Analysis [
          http://www.StockCall.com/MRK011613.pdf ]


    About StockCall.com  

    StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to
talk to our financial analyst at  

    http://www.stockcall.com   

StockCall.com

CONTACT:  Contact Person: William T. Knight, Email: info@stockcall.com,
Contact Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.